November 2016 Shareholder Presentation

With so many changes at AngioSoma, Inc. over the last month, we wanted to update our September 2016 shareholder presentation to correctly reflect what AngioSoma, Inc. has been doing.  We have made the November 2016 AngioSoma, Inc. Shareholder Presentation available in both the PDF version and embedded here in its Microsoft PowerPoint version:   © 2016 by Read more about November 2016 Shareholder Presentation[…]

AngioSoma, Inc. Files 3 New Patent Applications on Liprostin™

MONTGOMERY, Texas — (BUSINESS WIRE,October 11, 2016 09:00 AM Eastern Daylight Time) — AngioSoma, Inc. (OTCQB: SOAN) filed three (3) new patent applications associated with Liprostin™, adding to the Company’s product pipeline and supplementing the intellectual property already conveyed by Chairman Emeritus Dr. David P. “Doc” Summers, PhD, FACA. The new patents include transdermal skin Read more about AngioSoma, Inc. Files 3 New Patent Applications on Liprostin™[…]

AngioSoma, Inc. Announces a Liprostin™ Focused Joint Venture

MONTGOMERY, Texas–(BUSINESS WIRE)–AngioSoma, Inc. (OTCQB:SOAN) announces a joint venture with La Jolla Capital Partners LLC (‘La Jolla’) focused on the funding and management of US Food and Drug Administration (‘FDA’) Liprostin™ Phase III trials, as well as the licensing of Liprostin™ worldwide thereafter. Liprostin™ is a liposomal encapsulated prostaglandin e1 (‘PGE1’) and is AngioSoma, Inc.’s Read more about AngioSoma, Inc. Announces a Liprostin™ Focused Joint Venture[…]

AngioSoma, Inc. Welcomes Dr. Tom Garcia to Scientific Advisory Board

July 28, 2016 MONTGOMERY, Texas–(BUSINESS WIRE)– AngioSoma, Inc. (SOAN) (the ‘Company,’ ‘we,’ and ‘our‘), announces the formation of its scientific advisory board with the addition of A. Tomas Garcia III, MD, a practicing physician in the field of cardiology for the past 35 years and the immediate past president of the Texas Medical Association. Dr. Read more about AngioSoma, Inc. Welcomes Dr. Tom Garcia to Scientific Advisory Board[…]

AngioSoma’s Corporate Focus

July 14, 2016 09:00 AM Eastern Daylight Time MONTGOMERY, Texas–(BUSINESS WIRE)–AngioSoma, Inc. (OTCQB:SOAN), previously known as First Titan Corp. (the ‘Company‘, ‘we‘, and ‘our‘), changed our corporate name and focus to that of a clinical stage biopharmaceutical company introducing an exciting new treatment for one of the world’s most insidious and pervasive diseases, peripheral artery Read more about AngioSoma’s Corporate Focus[…]

First Titan Corp. Acquired AngioSoma, Inc.

HOUSTON, TX / ACCESSWIRE / June 22, 2016 / First Titan Corp. (OTCQB: FTTN) (the “First Titan”) is proud to announce the acquisition of AngioSoma, Inc., (OTCQB: SOAN) (the “Company”). The acquisition of AngioSoma, Inc. provides diversification for First Titan outside of the depressed oil & gas industry under the new name AngioSoma, Inc. and Read more about First Titan Corp. Acquired AngioSoma, Inc.[…]